which resembles intracellular fluid in ionic composition and strength. Twelve hours is usually quite sufficient time for transporting the kidney to the most suitable recipient and for making arrangements for the transplant operation. Occasionally longer periods of preservation are required and this can be achieved by perfusing the kidney on a special preservation machine. The machine perfuses the kidneys with a cold plasma-based fluid which is kept oxygenated and at the correct pH. During perfusion the viability of the kidney can be assessed in some measure, allowing severely damaged ones to be identified and discarded. Whether perfused kidneys function longer is a matter for debate. In an Australian series of cadaver transplants a greater percentage of perfused kidneys survived one year when compared with those that had merely been cooled (Sheil et al. 1975) . However, in a large series of transplants carried out in California this was not confirmed; in fact, in this study the perfused kidneys functioned for a considerably shorter time (Fine et al. 1975 ).
To prevent rejection of the kidney immunosuppressive drugs are given indefinitely. Initially prednisolone is administered in a high dose, but over ensuing weeks this can usually be reduced. Antilymphocyte globulin (ALG) has been shown to have remarkable immunosuppressive properties in animals, and as a result it has been used widely in man. However, there have been very few controlled clinical trials using this agent and even now it is not clear whether it is effective. In Australia a controlled trial demonstrated a beneficial effect of ALG (Sheil et al. 1971 ) but similar trials conducted in-the United States and elsewhere have failed to confirm this. A doubleblind controlled clinical trial is under way in the United Kingdom and its results are awaited with interest. Other drugs have been advocated as being helpful in preventing or delaying rejection. Anticoagulants came into vogue a few years ago but controlled studies reveal no benefit (Barnes et al. 1974) . The management of rejection episodes has altered. High doses of orally administered steroids can produce severe complications and it is now clear that rejection can be reversed as successfully by two or three intravenous 1 gram doses of methylprednisolone. The mortality associated with this treatment is much less than that which accompanies the use of high oral doses of prednisolone (Clarke & Salaman 1975) . The effect of previous blood transfusions on transplant survival has come under discussion. Previously it was thought that transfusing dialysis patients was unwise since a proportion would develop antibodies which could then react with a subsequent transplant. However, Terasaki and his co-workers have shown that a proportion of patients will not develop antibodies however many units of blood they receive (Opelz et al. 1972 ). These patients have been termed 'poor responders' and on receiving a kidney transplant appear to experience fewer rejection problems. In these prople blood transfusions may act in some beneficial way by generating enhancing antibodies. Certainly of the 'poor responder' patients those who have been deliberately deprived of blood transfusions do much less well after transplantation (Opelz & Terasaki 1974) .
Although serving a clinical need, kidney transplantation is not as successful as desired. Just under half the cadaver kidneys are lost, chiefly from rejection, within the first year after transplantation. Close tissue matching between donor and recipient has been the policy for a number of years in most centres in the UK, but what influence tissue matching has on kidney graft survival is still not clear. My personal belief is that the results of transplantation will improve only as a result of better immunosuppressive treatment. 
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Specific Suppression of Organ Graft Rejection
The scope of transplantation as a therapeutic procedure and its utility even in well-established areas such as renal failure are limited by the toxicity and inadequate potency of the immunosuppressive agents currently in use. These agents are largely nonspecific in their immunological effects and moreover they produce undesired side-effects outside the immune system. Specific immunosuppression directs itself solely at the lymphocyte clones responsible for the rejection of the particular graft the patient receives, and it 'Wellcome Senior Research Fellow in Clinical Science Section of Clinical Immunology & Allergy 529 is therefore free of the immunological and nonimmunological complications of current day therapy. If this approach could be used alone in clinical transplantation, immunosuppression would be perfectly safe, and this remains the ultimate aim of research in this area. For the immediate future, however, an approach which combines specific therapy with nonspecific agents on a low-dose and/or short-term basis offers the best hope of improving immunosuppression. By restricting the use of nonspecific agents in this way, their dangers can be virtually eliminated, and immunosuppression can be made safe. Whether or not this approach will also improve the potency of immunosuppression is at the moment not certain.
For specific immunosuppression with respect to a particular antigen one may treat the host either with the antigen itself or with antibodies directed against that antigen. In the transplant context, this involves treatment of the graft recipient with preparations containing donor histocompatibility antigens (active enhancement) or with antisera directed against these antigens (passive enhancement). As has been discussed in detail (Fabre 1976 ) active enhancement offers a number of practical and theoretical advantages over passive enhancement, not the least of which is that it is substantially more potent. However, the results of antigen therapy are far from predictable, and the risk of harming the patient by inducing sensitization is such that active enhancement is unlikely to be used clinically until there is more fundamental knowledge of the factors which influence the outcome of contact of the immune system with antigen. Passive enhancement has the virtue of safety, and it is also a simpler approach to specific immunosuppression. For these reasons it is the more clinically acceptable approach for the immediate future.
Work over the last few years, mainly with kidney grafts in inbred rats, has defined the broad framework within which passive enhancement is likely to be applied to clinical organ transplantation. There are important practical and theoretical problems associated with transfer from the inbred rat to the clinical situation, but these will be considered later. With inbred rats, passive enhancement involves, for example, treatment of Lewis recipients of DA or (DA x Lewis)Fl grafts with Lewis anti-DA serum. The 'enhancing' serum is prepared in advance in a separate group of rats, usually by hyperimmunization with donor strain lymphoid tissue. It is well established that optimal therapy involves administration of the enhancing serum at the time of grafting and for a few days thereafter (Stuart et al. 1968 . There is certainly no advantage in continuing antiserum administration beyond the first week.
From the clinical point of view there are several points to bear in mind:
(1) Though passive enhancement has been beneficial whenever it has been tested, its efficacy varies markedly across different histocompatibility barriers (as shown in Table 1 ). Across some barriers (e.g. AS2 to DA) it is completely effective. In others (e.g. August to AS) the F1 hybrid kidney is completely protected, but the homozygous kidney is only transiently protected. The most difficult barrier has been the DA to Lewis, where even the F1 hybrid graft is not completely protected. Since in the clinical situation one would be dealing with a broad spectrum of different histocompatibility barriers and one would have to assume the worst case, it is clearly not possible to contemplate the use of passive enhancement as the sole method of immunosuppression. Supplementary nonspecific therapy will be essential.
(2) It has been possible completely to protect kidney grafts across the strongest histocompatibility barrier so far tested in the rat by combining passive enhancement with a brief course of nonspecific immunosuppression in the form of antilymphocyte serum (ALS) during the first week after transplantation (Batchelor et al. 1972 , Fabre & Morris 1974a . The virtues of this approach have been outlined in the introductory paragraph. It has been disappointing that this Table I The effectiveness of passive enhancement of kidney grafts across different major histocompatibility barriers in the rat@ (Adapted from Fabre & Morris 1973 , 1974a and Fabre & Batchelor 1975a Mean ± I s.d. ofblood urea (mg/ IOOml) at
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Week 3 Week 20 Proc. roy. Soc. Med. Volume 69 July 1976 10 combination did not give impressive results with liver grafts in baboons (Myburgh & Smit 1973) , but this could be the result of a number of factors, especially the relative ineffectiveness of ALS, as it is currently used, in primates. Other nonspecific agents are currently being tested in conjunction with passive enhancement..
(3) The combination of passive enhancement plus a short course of ALS was not completely effective in presensitized recipients (Fabre & Morris 1975) . Though possibly disappointing, this result was not unexpected as sensitized recipients will resist virtually any attempt to induce complete graft acceptance. It means, however, that the prevention of sensitization will be essential for the optimal use of this approach to immunosuppression, and in the context of kidney (and heart) grafts, this means the prevention of sensitization by blood transfusions. The use of leukocyte-poor blood is one approach (Hugins et al. 1973) but another possible approach is treatment of the blood with antileukocyte antibodies (Fabre & Batchelor 1975b ).
There are two main problems with extrapolation of passive enhancement studies from the inbred rat to the clinical situation. The most important problem is that of specificity. In the inbred rat this presents no difficulties, since the donors and recipients of transplants are genetically identical to the donors and recipients used to produce the enhancing serum: DA to Lewis grafts are treated with Lewis anti-DA serum. It is clear that all donor incompatibilities will be covered in this situation, but it is a situation that can only rarely be duplicated in a randomly bred population such as the human. Any regimen of passive enhancement applicable to cadaver kidney transplantation and relying on complete cover of incompatibilities must rest on accurate tissue typing of donor and recipient and the use of sera raised in unrelated individuals against the incompatibilities detected. This raises serious potential difficulties, mainly because of the recently discovered complexity of the major histocompatibility system (MHS) (for review see Shreffler & David 1975) . This region seems to code for numerous antigens over and above the wellrecognized HLA antigens. Fortunately, a complete definition of the MHS will not be a prerequisite for the clinical application of passive enhancement, since it has been shown that one need cover only some of the donor incompatibilities for effective passive enhancement (Fabre & Morris 1974b , Staines et al. 1974 ).
The other main difficulty is hyperacute iejection. In most species studied, the presence in the recipient of antibodies directed against kidney graft antigens results in virtually immediate graft destruction. This is precipitated by complement fixation by the antibodies which attach, to the vascular endothelium. The problem reduces to preventing the ability of antibodies to fix complement without affecting their ability to induce enhancement. There are a number of approaches, but the most obvious is pepsin degradation of antibody to yield F(ab')2 fragments. Pepsindegraded antisera have been shown not to induce hyperacute rejection of kidney grafts (Holter et al. 1972 ) and also to retain their ability to induce enhancement (Myburgh & Smit 1972) , though this latter point requires more rigorous quantitative examination. For unknown reasons, the rat is fortunately relatively insusceptible to antibody-mediated kidney graft damage, so studies of passive enhancement can proceed in this species without taking the difficulty of hyperacute rejection into account.
There is a final point which should be stressed: the efficacy of passive enhancement is very much greater with organ grafts than with skin grafts. Indeed, it was not until the development of microsurgical techniques allowing organ transplants in inbred rats (Fisher & Lee 1965) that the clinical potential of passive enhancement became obvious. Until then, passive enhancement had been studied with skin grafts, where it could prolong graft survival by only 2 or 3 days. When applied to kidney grafts, it gave excellent results (Stuart et al. 1968 , French & Batchelor 1969 . The reasons for this striking difference between skin grafts on the one hand and organ grafts on the other are not known, but it means that passive enhancement will be of no clinical value for skincontaining grafts.
